Harvard Management Company’s Royalty Pharma RPRX Stock Holding History

Harvard Management Company’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,464,990	Closed	-$138M	–	47
2021 Q4	$138M	Sell	3,464,990 -3,677,866	-51%	-$143M	12.96%	3
2021 Q3	$258M	Hold	7,142,856	–	–	15.13%	2
2021 Q2	$293M	Sell	7,142,856 -3,571,428	-33%	-$152M	16.85%	2
2021 Q1	$467M	Sell	10,714,284 -3,976,496	-27%	-$189M	26.11%	1
2020 Q4	$735M	Hold	14,690,780	–	–	39.88%	1
2020 Q3	$618M	Hold	14,690,780	–	–	33.99%	1
2020 Q2	$713M	Buy	+14,690,780	New	+$727M	60.83%	1

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harvard Management Company's RPRX Position: Q1 2022 in Review

Harvard Management Company sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 3,464,990 shares — an estimated $138M sold.

Harvard Management Company first reported a position in RPRX in Q2 2020 and held it in 7 quarters. The position peaked at $735M in Q4 2020. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Harvard Management Company reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Harvard Management Company sold 3,464,990 Royalty Pharma shares in Q1 2022, an estimated $138M.
Harvard Management Company first reported a position in Royalty Pharma in Q2 2020 and held it in 7 quarters.
Harvard Management Company's Royalty Pharma position peaked at $735M in Q4 2020.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Harvard Management Company's 13F filing for Q1 2022, filed 13 May 2022.